Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alexion raises $120 million in notes

The 5.75 percent convertible subordinated notes

Read the full 62 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE